Perceptive Advisors LLC raised its position in shares of Dova Pharmaceuticals Inc (NASDAQ:DOVA) by 3.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,809,015 shares of the company’s stock after acquiring an additional 55,000 shares during the period. Dova Pharmaceuticals makes up 1.7% of Perceptive Advisors LLC’s portfolio, making the stock its 15th biggest position. Perceptive Advisors LLC owned about 7.05% of Dova Pharmaceuticals worth $52,099,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Fosun International Ltd boosted its position in shares of Dova Pharmaceuticals by 9.2% in the third quarter. Fosun International Ltd now owns 710,000 shares of the company’s stock worth $17,239,000 after buying an additional 60,000 shares during the period. Wells Fargo & Company MN boosted its position in shares of Dova Pharmaceuticals by 62.1% in the third quarter. Wells Fargo & Company MN now owns 324,287 shares of the company’s stock worth $7,874,000 after buying an additional 124,287 shares during the period. Goldman Sachs Group Inc. purchased a new stake in shares of Dova Pharmaceuticals in the second quarter worth about $493,000. Bank of New York Mellon Corp purchased a new stake in shares of Dova Pharmaceuticals in the third quarter worth about $340,000. Finally, Virtus Fund Advisers LLC purchased a new stake in shares of Dova Pharmaceuticals in the fourth quarter worth about $318,000. 26.05% of the stock is owned by hedge funds and other institutional investors.
Shares of Dova Pharmaceuticals Inc (DOVA) opened at $29.62 on Monday. Dova Pharmaceuticals Inc has a one year low of $16.98 and a one year high of $37.00.
DOVA has been the subject of several analyst reports. Zacks Investment Research downgraded Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 14th. BidaskClub upgraded Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, January 13th. Finally, Jefferies Group boosted their price target on Dova Pharmaceuticals to $33.00 and gave the stock a “buy” rating in a research note on Tuesday, November 28th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $32.75.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Want to see what other hedge funds are holding DOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dova Pharmaceuticals Inc (NASDAQ:DOVA).
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.